Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 9:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 247 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Rheumatoid Arthritis RA Clear all
Completed Phase 1Phase 2 Interventional Results available

Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

NCT00254293
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Abatacept or Placebo (both as IV & SC solution), Abatacept
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
5
States / cities
Orlando, Florida • Atlanta, Georgia • New Orleans, Louisiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Oct 6, 2026, 9:16 AM EDT
Not listed No phase listed Observational

Cardiovascular Outcomes in the VA's Rheumatoid Arthritis(VARA) Population

NCT00431405
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease, Coronary Disease
Interventions
Not listed
Lead sponsor
Dallas VA Medical Center
Federal
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2007 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 4 Interventional

Study of Adalimumab to Lower Cardiovascular Risk in RA Patients With Well Controlled Joint Disease

NCT01893996
View directory record Official record
Conditions
Rheumatoid Arthritis, Cardiovascular Disease
Interventions
Adalimumab, Placebo
Drug
Lead sponsor
Jonathan Graf
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2021 · Synced Oct 6, 2026, 9:16 AM EDT
Not listed No phase listed Observational

Interstitial Lung Disease in Early Rheumatoid Arthritis

NCT03977415
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 90 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 6, 2019 · Synced Oct 6, 2026, 9:16 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)

NCT00476996
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Leflunomide, Methotrexate, Ocrelizumab, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
836 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
144
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Oct 6, 2026, 9:16 AM EDT
Completed No phase listed Observational Results available

Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab

NCT01981473
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
no intervention
Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
605 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
34
States / cities
Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 29 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)

NCT02097524
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Sarilumab, Tocilizumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
19
States / cities
Birmingham, Alabama • Orange, California • DeLand, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 6, 2026, 9:16 AM EDT
Completed No phase listed Observational

Use of Thermal and 3D Imaging to Quantify Arthritis

NCT01044823
View directory record Official record
Conditions
Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis
Interventions
3D and thermal imaging
Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
4 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2017 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)

NCT02093026
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Rituximab, Methotrexate, Methylprednisolone, Folic Acid
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
21 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
42
States / cities
Birmingham, Alabama • Peoria, Arizona • Little Rock, Arkansas + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2017 · Synced Oct 6, 2026, 9:16 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis

NCT04539964
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Implant Procedure, Conventional Synthetic DMARD, Active stimulation, Non-active stimulation
Procedure · Drug · Device
Lead sponsor
SetPoint Medical Corporation
Industry
Eligibility
22 Years to 75 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
42
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 6, 2026, 9:16 AM EDT
Active, not recruiting Not applicable Interventional

At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]

NCT07163221
View directory record Official record
Conditions
Rheumatoid Arthritis (RA)
Interventions
Non-invasive ultrasound stimulation of the spleen - Treatment Setting 1, Non-invasive ultrasound stimulation of the spleen - Treatment Setting 2, Sham ultrasound stimulation (control), Conventional Synthetic DMARD
Device · Drug
Lead sponsor
SecondWave Systems Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
5
States / cities
Glendale, Arizona • Covina, California • Temecula, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 6, 2026, 9:16 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Strategy to Prevent the Onset of Clinically-Apparent Rheumatoid Arthritis

NCT02603146
View directory record Official record
Conditions
Healthy Participants, Rheumatoid Arthritis (RA) Prevention
Interventions
Hydroxychloroquine, HCQ Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2025 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 3 Interventional Results available

To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)

NCT01768572
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
sarilumab SAR153191 (REGN88), tocilizumab, hydroxychloroquine, methotrexate, sulfasalazine, leflunomide, subcutaneous placebo, intravenous placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
14
States / cities
Huntsville, Alabama • Colorado Springs, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 6, 2026, 9:16 AM EDT
Completed No phase listed Observational

A Study to Determine the Risk of Cancer in Rheumatoid Arthritis (RA) Patients Who Use Abatacept and Other Biologic Agents

NCT03670667
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Non-Interventional
Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 3 Interventional

Study of Eszopiclone Compared to Placebo on Daytime Function in Subjects With Insomnia Related to Rheumatoid Arthritis

NCT00367965
View directory record Official record
Conditions
Insomnia, Arthritis, Rheumatoid
Interventions
Eszopiclone, placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
25 Years to 64 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Santa Maria, California + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 1 Interventional

Safety Study of a Single Dose of REGN88(SAR153191)in Patients With Rheumatoid Arthritis

NCT01055899
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
REGN88
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
2
States / cities
Duncansville, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 30, 2013 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 4 Interventional

Efficacy and Safety of Valdecoxib and Naproxen in Treating the Signs and Symptoms of Rheumatoid Arthritis (RA) in a Severe Rheumatoid Arthritis Patients

NCT00650455
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
valdecoxib, naproxen, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
489 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
52
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2008 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of SC Injected Tc 99m Tilmanocept Localization in Active RA Subjects by SPECT and SPECT/CT Imaging

NCT02683421
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 21, 2019 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of GDC-0853 Compared With Placebo and Adalimumab in Participants With Rheumatoid Arthritis (RA)

NCT02833350
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853, Adalimumab, Folic Acid, MTX, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Anniston, Alabama • Glendale, Arizona • Covina, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 4 Interventional Results available

A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects

NCT02198651
View directory record Official record
Conditions
Rheumatoid Arthritis, Musculoskeletal and Connective Tissue Diseases
Interventions
Adalimumab, Placebo
Biological · Other
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
149 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
13
States / cities
Tuscaloosa, Alabama • Thousand Oaks, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 6, 2026, 9:16 AM EDT
Withdrawn Not applicable Interventional

Abatacept vs Placebo in RA Patients With Hepatitis B on Entecavir Background

NCT02053727
View directory record Official record
Conditions
Rheumatoid Arthritis, Chronic Hepatitis B
Interventions
Abatacept, Placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 6, 2026, 9:16 AM EDT
Completed No phase listed Observational

A Study of the Safety of Rituxan in Patients With Rheumatoid Arthritis After an Inadequate Response to Previous Anti-TNF Therapy (SUNSTONE)

NCT00443443
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Not listed
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,026 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
192
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 170 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2015 · Synced Oct 6, 2026, 9:16 AM EDT
Completed Phase 2 Interventional Results available

A Study in Patients With Rheumatoid Arthritis

NCT00966875
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LY2439821, Placebo
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
37
States / cities
Peoria, Arizona • La Mesa, California • Palm Desert, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 26, 2016 · Synced Oct 6, 2026, 9:16 AM EDT
Recruiting Phase 1 Interventional

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)

NCT06977724
View directory record Official record
Conditions
Dry Eye Syndrome, Systemic Lupus Erythematosus
Interventions
ABBV-319
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 6, 2026, 9:16 AM EDT